Barbara Harlin Bispham, serving as General Counsel and Corporate Secretary at CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO), executed a sale of 1,218 ordinary shares on June 22, 2026. The transaction, valued at $21,911, was conducted at prices ranging between $16.88 and $18.86 per share. This divestiture was necessitated by tax withholding requirements associated with the settlement of restricted stock units (RSUs) granted on December 15, 2025. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on February 25, 2026, specifically designed to cover taxes related to the vesting of these equity awards. Following this transaction, Bispham retains a direct ownership position of 19,330 ordinary shares in the company.
The stock currently trades at $17.50, with the company carrying a market capitalization of $585 million. Despite a strong 41% gain over the past six months, shares have declined nearly 4% in the past week. According to InvestingPro analysis, CBIO appears overvalued at current levels.
In other recent news, Crescent Biopharma has been the focus of several analyst evaluations and announcements. Cantor Fitzgerald reiterated its Overweight rating on Crescent Biopharma following Pfizer’s announcement of Phase 3 trial results for a competing drug candidate, which did not meet its primary endpoint. Similarly, Stifel maintained a Buy rating with a $30.00 price target for Crescent Biopharma, also referencing Pfizer’s trial data. However, H.C. Wainwright downgraded Crescent Biopharma to Neutral from Buy, due to less compelling competitive positioning for the company’s CR-001 candidate after recent clinical data.
Crescent Biopharma announced that its ASCEND study will be featured at the 2026 American Society of Clinical Oncology Annual Meeting. The ASCEND study is a global Phase 1/2 clinical trial evaluating CR-001 in patients with various solid tumor types, including non-small cell lung cancer. This trial is currently enrolling both treatment-naïve and previously treated patients. These developments highlight Crescent Biopharma’s ongoing efforts in advancing its clinical trials and the varied perspectives from analysts regarding its competitive landscape.